Use this guide one step at a time.
Bladder cancer decisions become clearer once you know whether the tumor has entered the bladder muscle and whether it is low, intermediate, high, or very high risk. Those distinctions affect the need for treatment inside the bladder, bladder removal, combined chemotherapy and radiation, or systemic therapy. It is also reasonable to discuss urinary function, sexual health, kidney function, work, and caregiving before choosing among treatments with different daily-life effects.
Key points
- For non-muscle-invasive cancer.
- For muscle-invasive disease, compare cystectomy-based and bladder-preserving pathways, including eligibility, treatment sequence, urinary effects, and the need for long-term surveillance.
Subtypes and biomarkers
Most bladder cancers are urothelial carcinomas. Pathology should also describe grade, depth, carcinoma in situ, lymphovascular invasion, and any variant histology, because these features can change risk and treatment. Squamous cell carcinoma, adenocarcinoma, small cell or neuroendocrine cancer, and other rare tumors follow different pathways; specialist pathology review can help when the type is uncommon. Non-muscle-invasive tumors include Ta, carcinoma in situ, and selected T1 disease, but their risk of recurrence or progression varies widely. Muscle-invasive disease reaches the muscular bladder wall and generally prompts a different treatment discussion. In locally advanced or metastatic urothelial cancer, tumor testing may look for FGFR alterations and other actionable features; biomarker results, prior therapy, kidney function, hearing, nerve symptoms, and overall fitness can affect systemic options. PD-L1 or other immune markers are not interchangeable, so ask exactly which decision a proposed test is meant to inform.
What is bladder cancer?
The bladder stores urine from the kidneys. Urothelial carcinoma accounts for most bladder cancers and can also arise elsewhere along the urinary tract. Less common bladder tumors include squamous cell carcinoma and adenocarcinoma. Tobacco exposure is the leading preventable risk factor; certain workplace chemicals, prior pelvic radiation or cyclophosphamide, chronic irritation, and some inherited factors also contribute. Non-muscle-invasive tumors remain in the lining or underlying connective tissue and vary from low to high risk. Muscle-invasive cancer has reached the muscular bladder wall and carries a greater risk of spread. Carcinoma in situ is flat, high-grade disease that can be difficult to see. Because recurrence is common, long-term cystoscopic surveillance is often required. In advanced disease, tumor biomarkers and eligibility for cisplatin help guide systemic treatment. Care depends on depth, stage, grade, risk group, biomarkers, kidney function, health, and preferences. Variant histology may alter management and can warrant specialist pathology review.
Signs and symptoms
Visible blood in urine, which may look pink, red, or cola-colored, is the most common sign and may come and go without pain. Microscopic blood may be found on a urine test. Other possible symptoms include frequent or urgent urination, burning or pain with urination, difficulty emptying the bladder, a weak stream, or waking often to urinate. More advanced disease may cause one-sided back or flank pain, pelvic pain, leg swelling, bone pain, fatigue, appetite loss, or unexplained weight loss. Urinary infection, stones, prostate enlargement, kidney disease, menstruation, medicines, and other noncancer causes can produce similar symptoms. Blood in urine should be evaluated even if it occurs once or resolves. Inability to urinate, heavy bleeding with clots, fever with urinary symptoms, or severe flank pain requires prompt or urgent care.
Diagnosis and staging
Evaluation includes history, examination, urinalysis, and often urine cytology. CT urography or other imaging examines the kidneys, ureters, bladder, and nearby structures. Cystoscopy allows direct inspection. Suspicious tissue is removed through transurethral resection of bladder tumor, which provides the diagnosis, grade, and depth; an adequate sample should include bladder muscle. A repeat resection may be needed for selected high-grade or incompletely sampled tumors. Additional CT, MRI, chest imaging, or bone evaluation assesses spread when appropriate. TNM staging describes invasion through bladder layers and nearby organs, lymph nodes, and distant metastases, producing stages 0 through IV. Non-muscle-invasive cancers are also assigned low, intermediate, or high recurrence and progression risk. Molecular testing, including selected markers or broader profiling, can guide treatment in advanced disease. Care depends on stage, grade, risk group, biomarkers, kidney function, health, and preferences. Upper-tract evaluation is important because urothelial tumors can occur at more than one urinary site. Examination under anesthesia may add local staging information during resection.
Established treatment paths
Non-muscle-invasive bladder cancer is initially treated with complete transurethral resection. A single dose of intravesical chemotherapy may follow, while intermediate- or high-risk disease often requires a course of intravesical chemotherapy or bacillus Calmette-Guérin with maintenance and close cystoscopic surveillance. Persistent very high-risk disease may lead to radical cystectomy. Muscle-invasive cancer is commonly treated with cisplatin-based chemotherapy before radical cystectomy and urinary diversion. Some people can pursue bladder-preserving trimodality therapy using maximal resection, concurrent chemotherapy, and radiation, with ongoing surveillance and salvage surgery if needed. Perioperative immunotherapy or other systemic treatment is used in selected high-risk situations. Locally advanced or metastatic urothelial cancer may receive antibody-drug conjugates, immunotherapy, platinum chemotherapy, targeted therapy for qualifying alterations, or combinations based on prior therapy, kidney function, biomarkers, and fitness. Radiation or procedures can relieve bleeding, pain, or obstruction. Clinical trials may be appropriate. Treatment planning should address urinary diversion, sexual function, fertility, kidney health, and quality of life. People receiving intravesical treatment need monitoring for urinary symptoms and, rarely, systemic infection. Surveillance intervals depend on risk and commonly continue for years because new tumors can develop.
Supportive care
Support needs vary with the treatment route. After transurethral resection or intravesical therapy, the team can help manage burning, urgency, frequency, bleeding, sleep disruption, and anxiety around repeated cystoscopy. Fever or systemic illness after BCG needs prompt assessment. Before cystectomy. Pelvic-floor rehabilitation, sexual-health care, fertility counseling, stoma support, and attention to hydration and kidney function can ease long-term adjustment. During chemotherapy or radiation, report worsening urinary pain, diarrhea, fatigue, neuropathy, hearing changes, or poor intake. Palliative care can help with pain, bleeding, obstruction, and decision support at any stage.
Profiles documenting bladder cancer care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
No clinic profile is connected to this guide yet. The wider directory may still offer useful places to explore.
Sources
Source information checked: 2026-10-01. The links below identify the public and clinic-provided materials used for this page.
- NCI: Bladder Cancer ↗Checked 2026-09-29
- NCI PDQ: Bladder Cancer Treatment ↗Checked 2026-09-29
- NCI: Bladder Cancer Treatment by Stage ↗Checked 2026-09-29
- NCI: Urinary and Bladder Problems ↗Checked 2026-10-01
- NCI: Sexual Health Issues in Men and Cancer Treatment ↗Checked 2026-10-01
- NCI: Sexual Health Issues in Women and Cancer Treatment ↗Checked 2026-10-01
How Cancer Clinic Finder compiles information · Suggest a factual correction
